Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51.
Japanese encephalitis virus (JEV) is the leading cause of viral encephalitis in Asia with a case fatality rate up to 35% and long-term sequelae up to 75%. This active-controlled, randomized, multi-centre, observer-blind, phase III trial investigated the neutralising antibody response to the new Japanese encephalitis (JE) vaccine IC51 in subjects with (N=81) and without (N=339) pre-existing tick-borne encephalitis (TBE) vaccine induced antibodies as determined by TBE enzyme-linked immunosorbent assay IgG (ELISA). Neutralising antibody response was statistically superior in TBE ELISA-positive subjects compared to TBE ELISA-negative subjects after the first (p<0.0001) but not after the second vaccination with IC51. Thus, pre-existing vaccine-induced TBE immunity enhances the neutralising JEV-specific antibody response after a single IC51 vaccination.
Schuller
Elisabeth
E
Intercell AG, Vienna Biocenter 6, Vienna, Austria.
Klade
Christoph S
CS
Heinz
Franz X
FX
Kollaritsch
Herwig
H
Rendi-Wagner
Pamela
P
Jilma
Bernd
B
Tauber
Erich
E
D000293:Adolescent; D000328:Adult; D000375:Aging / Q000276:immunology; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000276:immunology; D000918:Antibody Specificity; D002522:Chlorocebus aethiops; D003429:Cross Reactions; D004669:Encephalitis Viruses, Tick-Borne / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D022321:Japanese Encephalitis Vaccines / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D014709:Vero Cells; D055815:Young Adult
D000914:Antibodies, Viral; D022321:Japanese Encephalitis Vaccines